Study of absorption and elimination rate of Linagliptin tablets 5 mg in comparison with Linagliptin brand tablets (Tradjenta®).
Not Applicable
Not yet recruiting
- Conditions
- Bioequivalence study.
- Registration Number
- IRCT20200407046981N37
- Lead Sponsor
- Darmanyab darou pharmaceutical company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 24
Inclusion Criteria
The weight limit of each volunteer should be between 60 and 100 kg.
All volunteers must be non-smokers.
They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.
Candidates who have consented to the consent form.
Exclusion Criteria
Known hypersensitivity or idiosyncratic reaction to Linagliptin or any ingredients.
Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg.
Regular smoker who smokes more than ten cigarettes daily.
Taking any medicine during two weeks before dosing.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method